LIke ThisLIke ThisLIke This

Florence Bourgeois, MD, MPH

Florence Bourgeois MD MPH
Computational Health Informatics Program (CHIP)
Medicine Research
Emergency Medicine Research
Hospital Title:
Associate Physician in Medicine; Scientific Director, Biobank
Academic Title:
Assistant Professor of Pediatrics and Emergency Medicine, Harvard Medical School
Research Focus Area:
Drug RegulationResearch integrity
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

About Florence Bourgeois

Florence Bourgeois is an Assistant Professor of Pediatrics and Emergency Medicine at Harvard Medical School and is a member of the Division of Emergency Medicine and the Computational Health Informatics Program (CHIP) at Boston Children’s Hospital. She is a graduate of Yale University and Washington University School of Medicine in St. Louis. Dr. Bourgeois completed her residency training in pediatrics and fellowship in pediatric emergency medicine at Boston Children’s Hospital. She was a NRSA research fellow and obtained a Master In Public Health in clinical effectiveness at the Harvard School of Public Health. 

Research Overview

Dr. Bourgeois’ research interests are in the regulation and use of medications in children and the exploration of gaps and potential biases in current clinical evidence. She has performed extensive work analyzing drug trials and medication utilization in pediatric patient populations, with major research contributions related to quantifying the under-representation of children in clinical trials, defining the characteristics and quality of drug trials performed for pediatric drug approval, and measuring the correspondence between healthcare needs and research activity across a number of medical conditions and patient groups. She has examined the integration of evidence into clinical practice, focusing on clinician practices in the emergency room and on the impact of trial characteristics on research translation. In the area of research integrity, Dr. Bourgeois has conducted appraisals of clinical trials to address biases in the design and reporting of clinical trials, including publication bias and conflicts of interest. Her most recent work is centered on the use of regulatory documents to augment evidence-based data underpinning public health recommendations and medication utilization practices in children.

Key Publications

• Bourgeois F, Murthy S, Olson K, Pinto C, Ioannidis J, Mandl K. Pediatric Versus Adult Drug Trials for Conditions With High Pediatric Disease Burden. Pediatrics. 2012 Aug; 130(2):282-292.

• Murthy S, Mandl KD, Bourgeois F. Analysis of pediatric clinical drug trials for neuropsychiatric conditions. Pediatrics. 2013 Jun;131(6):1125-31.

• Hwang T, Kesselheim A, Bourgeois F. Postmarketing Trials and Pediatric Device Approvals. Pediatrics. 2014 April;133(5);e1197.

• Hwang TJ, Bourgeois F, Seeger JD. Drug Safety in the Digital Age. N Engl J Med. 2014 Jun 26;370(26):2460-2.

• Bourgeois F, Kim JM, Mandl KD. Premarket safety and efficacy studies for ADHD medications in children. PLoS One. 2014 Jul 9;9(7):e102249.

• Hwang TJ, Bourgeois F. New Regulatory Paradigms for Innovative Drugs to Treat Pediatric Diseases. JAMA Pediatr. 2014 Aug.

• Dunn A, Arachi D, Hudgins J, Tsafnat G, Coiera E, Bourgeois F. Financial Conflicts of Interest and Conclusions About Neuraminidase Inhibitors for Influenza. Annals of Internal Medicine. 2014 Oct;161:513-518.

Complete List of Published Work in MyBibliography 


Publications powered by Harvard Catalyst Profiles
  1. Pica N, Bourgeois F. Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children. Pediatrics. 2016 Sep; 138(3).
  2. Shah S, Bourgeois F, Mannix R, Nelson K, Bachur R, Neuman MI. Emergency Department Management of Febrile Respiratory Illness in Children. Pediatr Emerg Care. 2016 Jul; 32(7):429-34.
  3. Bourgeois FT, Olson KL, Tse T, Ioannidis JP, Mandl KD. Prevalence and Characteristics of Interventional Trials Conducted Exclusively in Elderly Persons: A Cross-Sectional Analysis of Registered Clinical Trials. PLoS One. 2016; 11(5):e0155948.
  4. Lebowitz MB, Olson KL, Burns M, Harper MB, Bourgeois F. Drug-Drug Interactions Among Hospitalized Children Receiving Chronic Antiepileptic Drug Therapy. Hosp Pediatr. 2016 May; 6(5):282-9.
  5. Hudgins JD, Fine AM, Bourgeois FT. Effect of Randomized Clinical Trial Findings on Emergency Management. Acad Emerg Med. 2016 Jan; 23(1):36-47.
  6. Hawkins JB, Brownstein JS, Tuli G, Runels T, Broecker K, Nsoesie EO, McIver DJ, Rozenblum R, Wright A, Bourgeois FT, Greaves F. Measuring patient-perceived quality of care in US hospitals using Twitter. BMJ Qual Saf. 2016 Jun; 25(6):404-13.
  7. Bourgeois FT, Olson KL, Poduri A, Mandl KD. Comparison of Drug Utilization Patterns in Observational Data: Antiepileptic Drugs in Pediatric Patients. Paediatr Drugs. 2015 Oct; 17(5):401-10.
  8. Monuteaux MC, Bourgeois FT, Mannix R, Samnaliev M, Stack AM. Variation and Trends in Charges for Pediatric Care in Massachusetts Emergency Departments, 2000-2011. Acad Emerg Med. 2015 Oct; 22(10):1164-71.
  9. Murthy S, Mandl KD, Bourgeois FT. Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013. Health Res Policy Syst. 2015; 13:28.
  10. Dunn AG, Arachi D, Bourgeois FT. Identifying Clinical Study Types from PubMed Metadata: The Active (Machine) Learning Approach. Stud Health Technol Inform. 2015; 216:867-71.
  11. Show all
  12. Zhou X, Wang Y, Tsafnat G, Coiera E, Bourgeois FT, Dunn AG. Citations alone were enough to predict favorable conclusions in reviews of neuraminidase inhibitors. J Clin Epidemiol. 2015 Jan; 68(1):87-93.
  13. Dunn AG, Arachi D, Hudgins J, Tsafnat G, Coiera E, Bourgeois FT. Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. Ann Intern Med. 2014 Oct 7; 161(7):513-8.
  14. Hwang TJ, Bourgeois FT. New regulatory paradigms for innovative drugs to treat pediatric diseases. JAMA Pediatr. 2014 Oct; 168(10):879-80.
  15. Bourgeois FT, Monuteaux MC, Stack AM, Neuman MI. Variation in emergency department admission rates in US children's hospitals. Pediatrics. 2014 Sep; 134(3):539-45.
  16. Bourgeois FT, Kim JM, Mandl KD. Premarket safety and efficacy studies for ADHD medications in children. PLoS One. 2014; 9(7):e102249.
  17. Hwang TJ, Bourgeois FT, Seeger JD. Drug safety in the digital age. N Engl J Med. 2014 Jun 26; 370(26):2460-2.
  18. Hwang TJ, Kesselheim AS, Bourgeois FT. Postmarketing trials and pediatric device approvals. Pediatrics. 2014 May; 133(5):e1197-202.
  19. Dunn AG, Mandl KD, Coiera E, Bourgeois FT. The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children. PLoS One. 2013; 8(12):e84951.
  20. Bourgeois FT, Olson KL, Ioannidis JP, Mandl KD. Association between pediatric clinical trials and global burden of disease. Pediatrics. 2014 Jan; 133(1):78-87.
  21. Burghardt LC, Ayers JW, Brownstein JS, Bronstein AC, Ewald MB, Bourgeois FT. Adult prescription drug use and pediatric medication exposures and poisonings. Pediatrics. 2013 Jul; 132(1):18-27.
  22. Tay KY, Ewald MB, Bourgeois FT. Use of QT-prolonging medications in US emergency departments, 1995-2009. Pharmacoepidemiol Drug Saf. 2014 Jan; 23(1):9-17.
  23. Murthy S, Mandl KD, Bourgeois F. Analysis of pediatric clinical drug trials for neuropsychiatric conditions. Pediatrics. 2013 Jun; 131(6):1125-31.
  24. Dunn AG, Bourgeois FT, Coiera E. Industry influence in evidence production. J Epidemiol Community Health. 2013 Jul; 67(7):537-8.
  25. Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JP, Mandl KD. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012 Aug; 130(2):285-92.
  26. Dunn AG, Bourgeois FT, Murthy S, Mandl KD, Day RO, Coiera E. The role and impact of research agendas on the comparative-effectiveness research among antihyperlipidemics. Clin Pharmacol Ther. 2012 Apr; 91(4):685-91.
  27. Bourgeois FT, Murthy S, Mandl KD. Comparative effectiveness research: an empirical study of trials registered in PLoS One. 2012; 7(1):e28820.
  28. Mannix R, Nigrovic LE, Schutzman SA, Hennelly K, Bourgeois FT, Meehan WP, Fleisher G, Monuteaux M, Lee LK. Factors associated with the use of cervical spine computed tomography imaging in pediatric trauma patients. Acad Emerg Med. 2011 Sep; 18(9):905-11.
  29. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010 Sep; 19(9):901-10.
  30. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in Ann Intern Med. 2010 Aug 3; 153(3):158-66.
  31. Mannix R, Bourgeois FT, Schutzman SA, Bernstein A, Lee LK. Neuroimaging for pediatric head trauma: do patient and hospital characteristics influence who gets imaged? Acad Emerg Med. 2010 Jul; 17(7):694-700.
  32. Bourgeois FT, Valim C, McAdam AJ, Mandl KD. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics. 2009 Dec; 124(6):e1072-80.
  33. Bourgeois FT, Mandl KD, Valim C, Shannon MW. Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics. 2009 Oct; 124(4):e744-50.
  34. Bourgeois FT, Shannon MW, Stack AM. "Left without being seen": a national profile of children who leave the emergency department before evaluation. Ann Emerg Med. 2008 Dec; 52(6):599-605.
  35. Bourgeois FT, Simons WW, Olson K, Brownstein JS, Mandl KD. Evaluation of influenza prevention in the workplace using a personally controlled health record: randomized controlled trial. J Med Internet Res. 2008; 10(1):e5.
  36. Bourgeois FT, Porter SC, Valim C, Jackson T, Cook EF, Mandl KD. The value of patient self-report for disease surveillance. J Am Med Inform Assoc. 2007 Nov-Dec; 14(6):765-71.
  37. Bourgeois FT, Shannon MW. Emergency care for children in pediatric and general emergency departments. Pediatr Emerg Care. 2007 Feb; 23(2):94-102.
  38. Bourgeois FT, Valim C, Wei JC, McAdam AJ, Mandl KD. Influenza and other respiratory virus-related emergency department visits among young children. Pediatrics. 2006 Jul; 118(1):e1-8.
  39. Kimia A, Brownstein JS, Olson KL, Zak V, Bourgeois FT, Mandl KD. Lumbar puncture ordering and results in the pediatric population: a promising data source for surveillance systems. Acad Emerg Med. 2006 Jul; 13(7):767-73.
  40. Bourgeois FT, Olson KL, Brownstein JS, McAdam AJ, Mandl KD. Validation of syndromic surveillance for respiratory infections. Ann Emerg Med. 2006 Mar; 47(3):265.e1.
  41. James CA, Bourgeois FT, Shannon MW. Association of race/ethnicity with emergency department wait times. Pediatrics. 2005 Mar; 115(3):e310-5.
  42. Bourgeois FT, Shannon MW. Adult patient visits to children's hospital emergency departments. Pediatrics. 2003 Jun; 111(6 Pt 1):1268-72.
  43. Bourgeois FT, Shannon MW. Retropharyngeal cellulitis in a 5-week-old infant. Pediatrics. 2002 Mar; 109(3):E51.
LIke ThisLIke ThisLIke This